Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MolMed and GSK sign gene therapy deal

This article was originally published in Scrip

Executive Summary

Italy's MolMed has signed a strategic agreement with GlaxoSmithKline to provide gene therapy services to the UK company. The deal is worth €34m over five years in up-front, milestone, service and supply payments. It follows earlier agreements under which MolMed undertook to design the production process and subsequently continue to manufacture GSK's investigational gene therapy for the ultra-rare, life-threatening condition Adenosine Deaminase Deficiency - Severe Combined Immune Deficiency (ADA-SCID). In 2010 GSK formed an alliance with Fondazione Telethon and Fondazione San Raffaele (MolMed was spun out of the San Raffaele Scientific Institute) to address rare diseases using gene therapy carried out on stem cells taken from the patient's bone marrow. The deal focused on ADA-SCID and six further applications of ex vivo stem cell therapy. The current deal specifies that MolMed will supply development, manufacturing and tech transfer services for the clinical application of gene therapies based on viral vector cellular transduction. MolMed chairman and CEO Claudio Bordignon said the agreement "acknowledges the substantial investment the company has made in its development labs and in additional production facilities, ultimately placing MolMed in a leadership position in the global industry."

You may also be interested in...

Speedy Approval Of Gilead’s Veklury Sets Stage For Pediatric Expansion, Dosing Refinement

US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.

Adolescents In COVID-19 Vaccine Trials: As Pfizer Starts Dosing, US FDA Encouraging Other Sponsors

But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.

Finance Watch: A SPACtacular Week For Biopharma Deals And Dollars

Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts